Summary & Overview
CPT 0021U: Apifiny® Prostate Cancer Autoantibody Risk Assay
CPT code 0021U is a Proprietary Laboratory Analyses (PLA) code for Apifiny®, a serum immunoassay combined with flow cytometry that measures eight autoantibodies and applies an algorithm to produce a prostate cancer risk score. As a PLA code, 0021U is specific to a single manufacturer's test and signals an emerging, proprietary diagnostic intended to support clinical decision-making in prostate cancer risk assessment. Nationally, PLA codes like 0021U are important because they capture use of novel, vendor-specific laboratory tests that may influence screening pathways and referral patterns.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the test, the typical service setting and type, and a summary of payer coverage patterns where available. The publication also outlines commonly reported modifiers and identifies where input data were not provided.
This report helps clinicians, laboratory administrators, and policy analysts understand what CPT code 0021U represents, why it matters in national billing and diagnostic practice, and what to expect in terms of payer engagement and documentation requirements. Data not available in the input are noted where relevant.
Billing Code Overview
CPT code 0021U is a Proprietary Laboratory Analyses (PLA) code that describes the Apifiny® test by Armune Bioscience, Inc. The test is an immunoassay and flow cytometry serum panel measuring eight autoantibodies and uses a proprietary algorithm to report a risk score for prostate cancer.
Service Type: Laboratory diagnostic test (proprietary serum immunoassay with flow cytometry and algorithmic risk reporting)
Typical Site of Service: Clinical laboratory or reference laboratory; specimen collected in outpatient or ambulatory settings
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with a rising prostate-specific antigen (PSA) level and a prior negative prostate biopsy presents for further risk stratification. The clinician orders the Apifiny® assay (0021U), a proprietary serum immunoassay combined with flow cytometry and an algorithm that reports an individualized risk score for clinically significant prostate cancer. Blood is drawn in an outpatient clinic or ambulatory laboratory; the specimen is sent to the manufacturer's reference laboratory. The laboratory performs immunoassays and flow cytometry for eight autoantibodies and runs the proprietary algorithm to generate a risk score. Results are returned to the ordering urologist or primary care clinician to inform decisions about repeat biopsy, imaging (such as multiparametric MRI), or active surveillance. Typical site of service is outpatient clinic, ambulatory surgical center for associated urologic procedures, or reference laboratory processing. Common patient scenario: elevated or rising PSA, family history of prostate cancer, abnormal digital rectal exam, or prior indeterminate biopsy where additional noninvasive risk stratification is desired.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default - no modifier | Use when no specific modifier is applicable to the service billed. |